This trial is investigating a potential new treatment in people with obesity and a history of cardiovascular disease. The new treatment, called ‘CagriSema’, is a combination of two medications:
1. cagrilinitide - acts in the same way as the hormone amylin, to stop you from getting hungry and to make you feel full and;
2. semaglutide - currently used to treat type 2 diabetes and for weight management, by acting in the same way as another hormone (glucagon-like-peptide-1) which suppresses appetite and helps regulate blood sugar.
Study participation will be up to 3 years and involves a screening visit to confirm eligibility, a treatment period, and a follow up after the final treatment. Study participants will be supplied with the study treatment and provided in an injector pen, for self-administration at home. There will be no cost to be involved in the study and travel expenses will be reimbursed.
Inclusion Criteria:
· Age 55 years or older
· You have had a stroke, a heart attack (myocardial infarction), or have poor circulation (arterial disease)
· You are living with obesity (BMI > 30kg/m2)
· You may have type 2 diabetes
· You are able to attend regular clinic visits and received phone calls over a period of 3 years
Further inclusion criteria apply
Exclusion Criteria:
· You have been diagnosed with:
- Heart failure
- Type 1 diabetes
- Chronic pancreatitis
- Significant kidney (renal) disease
Further exclusion criteria apply
Further information can be found at https://clinicaltrials.gov/ct2/show/NCT05669755
To register - please complete detaisl below or email us at info@clinitrials.com.au